Manmeet Singh Soni - 28 Feb 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role: COO, CFO and President
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 28 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 01 Mar 2023, 15:16:21 UTC
Previous filing: 04 Jan 2023
Next filing: 06 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+75,000		$0.000000	75,000	28 Feb 2023	Class A common stock	75,000	$34.15	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 16, 2022, the reporting person was granted an option to purchase 75,000 shares of Class A common stock. On February 28, 2023 based on the satisfaction of certain performance criteria, the option vested as to 14,063 shares and is set to vest 1/16th of the original grant on each three month anniversary such that 100% of the options will be vested on the four-year anniversary of the date of grant, subject to continued service through each vesting date.

Content

On September 16, 2022, the reporting person was granted an option to purchase 75,000 shares of Class A common stock. On February 28, 2023 based on the satisfaction of certain performance criteria, the option vested as to 14,063 shares and is set to vest 1/16th of the original grant on each three month anniversary such that 100% of the options will be vested on the four-year anniversary of the date of grant, subject to continued service through each vesting date.